NodThera ’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

BOSTON, MA, March 7, 2024– NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa study...

Source: Drugs.com - Clinical Trials - March 7, 2024 Category: Pharmaceuticals Source Type: clinical trials